title: Mechanism of rethrombosis after thrombolytic therapy: angioscopic findings and investigation of the coagulation system in dogs.
abstract: The purpose of this study was to angioscopically observe the process of thrombolysis after intracoronary administration of thrombolytic agents and to investigate the effects of these agents on coagulation/fibrinolysis systems in dogs. The coronary endothelium was removed and thrombus formation was confirmed by angioscopy. In the tissue plasminogen activator (tPA) group (n=8), complete thrombolysis occurred in all animals, but thrombolysis was incomplete in the urokinase (UK) group (n=6). The plasma level of plasmin alpha2-plasmin inhibitor complex peaked at 15 minutes after treatment in both the tPA and UK groups. Plasma thrombin-antithrombin III (TAT) complex decreased transiently at 15 minutes after tPA administration but increased at 30 and 60 minutes (P<0.05). In the UK group, plasma TAT also showed a transient decrease followed by an increase, which was minimal compared with that in the tPA group. Plasma TAT decreased transiently after infusion of tPA and subsequently increased to above the pretreatment level, suggesting a risk of rethrombosis after successful recanalization.
authors.affiliation: Second Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Maki
authors.forename: C
authors.initials: C
authors.lastname: Shirato
authors.forename: M
authors.initials: M
authors.lastname: Ohguchi
authors.forename: N
authors.initials: N
authors.lastname: Aoki
authors.forename: N
authors.initials: N
authors.lastname: Ochiai
authors.forename: S
authors.initials: S
authors.lastname: Taguchi
authors.forename: I
authors.initials: I
authors.lastname: Aoki
authors.forename: K
authors.initials: K
authors.lastname: Ishikawa
mesh_terms: D017546:Angioscopy; D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology; D003331:Coronary Vessels; D004285:Dogs; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects* / Q000502:physiology; D008297:Male; D010960:Plasminogen Activators / Q000627:therapeutic use*; D012008:Recurrence; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000979:alpha-2-Antiplasmin / Q000032:analysis
chemical_list: D000979:alpha-2-Antiplasmin; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator